Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Tóm tắt
Từ khóa
Tài liệu tham khảo
Addie, 2013, Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases, J Med Chem, 56, 2059, 10.1021/jm301762v
Alessi, 1997, Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha, Curr Biol, 7, 261, 10.1016/S0960-9822(06)00122-9
Alessi, 2009, New insights into mTOR signaling: mTORC2 and beyond, Sci Signal, 2, pe27, 10.1126/scisignal.267pe27
Andjelković, 1997, Role of translocation in the activation and function of protein kinase B, J Biol Chem, 272, 31515, 10.1074/jbc.272.50.31515
Baselga, 2012, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 366, 520, 10.1056/NEJMoa1109653
Bellacosa, 1995, Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas, Int J Cancer, 64, 280, 10.1002/ijc.2910640412
Bendell, 2012, Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors, J Clin Oncol, 30, 282, 10.1200/JCO.2011.36.1360
Bhagwat, 2011, Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin, Mol Cancer Ther, 10, 1394, 10.1158/1535-7163.MCT-10-1099
Blaser, 2012, Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells, BMC Cancer, 12, 86, 10.1186/1471-2407-12-86
Burris, 2013, Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway, Cancer Chemother Pharmacol, 71, 829, 10.1007/s00280-012-2043-3
Cantley, 2002, The phosphoinositide 3-kinase pathway, Science, 296, 1655, 10.1126/science.296.5573.1655
Cappellano, 2013, Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex, Childs Nerv Syst, 10.1007/s00381-013-2170-0
Carpten, 2007, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, 448, 439, 10.1038/nature05933
Carracedo, 2008, The PTEN–PI3K pathway: of feedbacks and cross-talks, Oncogene, 27, 5527, 10.1038/onc.2008.247
Carretero, 2010, Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors, Cancer Cell, 17, 547, 10.1016/j.ccr.2010.04.026
cBioPortal for Cancer Genomics
Chalhoub, 2009, PTEN and the PI3-kinase pathway in cancer, Annu Rev Pathol, 4, 127, 10.1146/annurev.pathol.4.110807.092311
Cheng, 1992, AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas, Proc Natl Acad Sci U S A, 89, 9267, 10.1073/pnas.89.19.9267
Cheng, 2011, Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011, JOP, 12, 334
Cheung, 2011, High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability, Cancer Discov, 1, 170, 10.1158/2159-8290.CD-11-0039
Cheung, 2013, Diverse mechanisms of AKT pathway activation in human malignancy, Curr Cancer Drug Targets, 13, 234, 10.2174/1568009611313030002
Contreras, 2010, Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy, Dis Model Mech, 3, 181, 10.1242/dmm.004440
COSMIC (Catalogue of Somatic Mutations in Cancer)
Davies, 2008, A novel AKT3 mutation in melanoma tumours and cell lines, Br J Cancer, 99, 1265, 10.1038/sj.bjc.6604637
Di Nicolantonio, 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus, J Clin Invest, 120, 2858, 10.1172/JCI37539
Engelman, 2009, Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nat Rev Cancer, 9, 550, 10.1038/nrc2664
Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat Med, 14, 1351, 10.1038/nm.1890
Engelman, 2006, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat Rev Genet, 7, 606, 10.1038/nrg1879
European Chromosome 16 Tuberous Sclerosis Consortium, 1993, Identification and characterization of the tuberous sclerosis gene on chromosome 16, Cell, 75, 1305, 10.1016/0092-8674(93)90618-Z
Furet, 2013, Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation, Bioorg Med Chem Lett, 23, 3741, 10.1016/j.bmcl.2013.05.007
García, 2004, Promoter methylation of the PTEN gene is a common molecular change in breast cancer, Genes Chromosomes Cancer, 41, 117, 10.1002/gcc.20062
Goel, 2004, Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers, Cancer Res, 64, 3014, 10.1158/0008-5472.CAN-2401-2
Hardie, 2012, AMPK: a nutrient and energy sensor that maintains energy homeostasis, Nat Rev Mol Cell Biol, 13, 251, 10.1038/nrm3311
Hashimoto, 2004, Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH, Mod Pathol, 17, 617, 10.1038/modpathol.3800107
Hayes, 2006, PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia, Clin Cancer Res, 12, 5932, 10.1158/1078-0432.CCR-06-1375
Hong, 2012, A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors, Clin Cancer Res, 18, 4173, 10.1158/1078-0432.CCR-12-0714
Hopkins, 2013, A secreted PTEN phosphatase that enters cells to alter signaling and survival, Science (New York, N.Y.), 341, 399, 10.1126/science.1234907
Huang, 2007, The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations, Science, 318, 1744, 10.1126/science.1150799
Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838
Ichimura, 2008, 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas, Oncogene, 27, 2097, 10.1038/sj.onc.1210848
Ihle, 2009, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res, 69, 143, 10.1158/0008-5472.CAN-07-6656
Iyer, 2012, Genome sequencing identifies a basis for everolimus sensitivity, Science, 338, 221, 10.1126/science.1226344
Jaber, 2012, Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function, Proc Natl Acad Sci U S A, 109, 2003, 10.1073/pnas.1112848109
Janes, 2013, Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia, Leukemia, 27, 586, 10.1038/leu.2012.276
Janku, 2013, Bringing target-matched PI3King from the bench to the clinic, Cell Cycle, 12, 1817, 10.4161/cc.25118
Janku, 2012, PTEN assessment and PI3K/mTOR inhibitors: importance of simultaneous assessment of MAPK pathway aberrations, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.10510
Janku, 2011, Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors, Cancer Res, 71
Janku, 2012, Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 patients and experience with early-phase protocols with PI3K/AKT/mTOR inhibitors, Eur J Cancer, 48, 76, 10.1016/S0959-8049(12)72044-0
Janku, 2011, Autophagy as a target for anticancer therapy, Nat Rev Clin Oncol, 8, 528, 10.1038/nrclinonc.2011.71
Janku, 2013, Abstract no. 804: Phase Ib study of oral pan-PI3K BKM120 in combination with the oral MEK1/2 inhibitor GSK120212 in patients with selected advanced solid tumors and RAS/BRAF mutations
Janku, 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors, Mol Cancer Ther, 10, 558, 10.1158/1535-7163.MCT-10-0994
Janku, 2013, PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials, Cancer Res, 73, 276, 10.1158/0008-5472.CAN-12-1726
Janku, 2012, PIK3CA mutations in advanced cancers: characteristics and outcomes, Oncotarget, 3, 1566, 10.18632/oncotarget.716
Janku, 2012, PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations, J Clin Oncol, 30, 777, 10.1200/JCO.2011.36.1196
Jia, 2008, Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis, Nature, 454, 776, 10.1038/nature07091
Juric, 2012, Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC), Cancer Res, 72
Juric, 2012, BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study, Cancer Res, 72
Kang, 2008, Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma, Int J Gynecol Cancer, 18, 1339, 10.1111/j.1525-1438.2007.01172.x
Knuefermann, 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells, Oncogene, 22, 3205, 10.1038/sj.onc.1206394
Kohrman, 2012, Emerging treatments in the management of tuberous sclerosis complex, Pediatr Neurol, 46, 267, 10.1016/j.pediatrneurol.2012.02.015
Kok, 2009, Regulation of phosphoinositide 3-kinase expression in health and disease, Trends Biochem Sci, 34, 115, 10.1016/j.tibs.2009.01.003
Kuwada, 2011, A rationale for mTOR inhibitors as chemoprevention agents in Peutz–Jeghers syndrome, Fam Cancer, 10, 469, 10.1007/s10689-011-9471-9
Lee, 1999, Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association, Cell, 99, 323, 10.1016/S0092-8674(00)81663-3
Li, 1997, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science, 275, 1943, 10.1126/science.275.5308.1943
Lin, 2013, Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models, Clin Cancer Res, 19, 1760, 10.1158/1078-0432.CCR-12-3072
Liu, 2009, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat Rev Drug Discov, 8, 627, 10.1038/nrd2926
Lui, 2013, Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers, Cancer Discov, 3, 761, 10.1158/2159-8290.CD-13-0103
Ma, 2012, Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells, PloS one, 7, e46055, 10.1371/journal.pone.0046055
Macias-Perez, 2013, GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia, Curr Hematol Malig Rep, 8, 22, 10.1007/s11899-012-0142-1
Maehama, 1998, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate, J Biol Chem, 273, 13375, 10.1074/jbc.273.22.13375
Mahadevan, 2012, Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies, Eur J Cancer, 48, 3319, 10.1016/j.ejca.2012.06.027
Mahoney, 2009, LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition, Br J Cancer, 100, 370, 10.1038/sj.bjc.6604886
Manning, 2003, Rheb fills a GAP between TSC and TOR, Trends Biochem Sci, 28, 573, 10.1016/j.tibs.2003.09.003
Markman, 2010, Targeting the PI3K/Akt/mTOR pathway—beyond rapalogs, Oncotarget, 1, 530, 10.18632/oncotarget.188
May, 2011, PD09-05: SU2C phase Ib study of pan-PI3K inhibitor BKM120 plus aromatase inhibitor letrozole in ER+/HER2− metastatic breast cancer (MBC), Cancer Res, 71
McCormack, 2011, Efficacy and safety of sirolimus in lymphangioleiomyomatosis, N Engl J Med, 364, 1595, 10.1056/NEJMoa1100391
Miwa, 1996, Isolation of DNA sequences amplified at chromosome 19q13.1–q13.2 including the AKT2 locus in human pancreatic cancer, Biochem Biophys Res Commun, 225, 968, 10.1006/bbrc.1996.1280
Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9
Nagaraj, 2012, A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.tps664
Naing, 2012, Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma, Br J Cancer, 107, 1093, 10.1038/bjc.2012.368
Ni, 2012, Functional characterization of an isoform-selective inhibitor of PI3K–p110β as a potential anticancer agent, Cancer Discov, 2, 425, 10.1158/2159-8290.CD-12-0003
O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925
Ogita, 2011, Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs, Target Oncol, 6, 103, 10.1007/s11523-011-0176-7
Pal, 2010, Akt inhibitors in clinical development for the treatment of cancer, Expert Opin Investig Drugs, 19, 1355, 10.1517/13543784.2010.520701
Papa, 2013, Pills of PTEN? In and out for tumor suppression, Cell Research, 23, 1155, 10.1038/cr.2013.103
Piha-Paul, 2011, Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus)-based treatment, J Clin Oncol, 29, e333, 10.1200/JCO.2010.32.5928
Pike, 2013, Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014, Bioorg Med Chem Lett, 23, 1212, 10.1016/j.bmcl.2013.01.019
Polivka, 2012, New molecularly targeted therapies for glioblastoma multiforme, Anticancer Res, 32, 2935
Prasad, 2011, Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide, Neuro Oncol, 13, 384, 10.1093/neuonc/noq193
Putz, 2012, The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells, Science Signaling, 5, ra70, 10.1126/scisignal.2003084
Pymar, 2008, Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms, Hum Mol Genet, 17, 2006, 10.1093/hmg/ddn098
Reynolds, 2013, Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program, Pediatr Blood Cancer, 60, 791, 10.1002/pbc.24301
Rodon, 2013, Development of PI3K inhibitors: lessons learned from early clinical trials, Nat Rev Clin Oncol, 10, 143, 10.1038/nrclinonc.2013.10
Rodrik-Outmezguine, 2011, mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling, Cancer Discov, 1, 248, 10.1158/2159-8290.CD-11-0085
Ruggeri, 1998, Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas, Mol Carcinog, 21, 81, 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R
Samuels, 2004, High frequency of mutations of the PIK3CA gene in human cancers, Science, 304, 554, 10.1126/science.1096502
Sato, 2010, Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer, Oncogene, 29, 2746, 10.1038/onc.2010.28
Shackelford, 2013, LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin, Cancer Cell, 23, 143, 10.1016/j.ccr.2012.12.008
Shaw, 2006, Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, 441, 424, 10.1038/nature04869
Shaw, 2004, The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress, Proc Natl Acad Sci U S A, 101, 3329, 10.1073/pnas.0308061100
Smolarek, 1998, Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis, Am J Hum Genet, 62, 810, 10.1086/301804
So, 2013, Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function, J Biol Chem, 288, 5718, 10.1074/jbc.M112.379446
Song, 2012, The functions and regulation of the PTEN tumour suppressor, Nat Rev Mol Cell Biol, 13, 283, 10.1038/nrm3330
Stahl, 2004, Deregulated Akt3 activity promotes development of malignant melanoma, Cancer Res, 64, 7002, 10.1158/0008-5472.CAN-04-1399
Steck, 1997, Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers, Nat Genet, 15, 356, 10.1038/ng0497-356
Stephens, 1997, The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101, Cell, 89, 105, 10.1016/S0092-8674(00)80187-7
Stern, 2008, ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer, J Mammary Gland Biol Neoplasia, 13, 215, 10.1007/s10911-008-9083-7
Sun, 2013, mTOR kinase inhibitors as potential cancer therapeutic drugs, Cancer Lett, 10.1016/j.canlet.2013.06.017
Sznol, 2013, Studies of NVP-BEZ235 in melanoma, Curr Cancer Drug Targets, 13, 165, 10.2174/1568009611313020006
Van Slegtenhorst, 1997, Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34, Science, 277, 805, 10.1126/science.277.5327.805
Vanhaesebroeck, 2010, The emerging mechanisms of isoform-specific PI3K signalling, Nat Rev Mol Cell Biol, 11, 329, 10.1038/nrm2882
Vasudevan, 2009, AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer, Cancer Cell, 16, 21, 10.1016/j.ccr.2009.04.012
Wagner, 2010, Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors, J Clin Oncol, 28, 835, 10.1200/JCO.2009.25.2981
Wallin, 2011, GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway, Mol Cancer Ther, 10, 2426, 10.1158/1535-7163.MCT-11-0446
Weigelt, 2011, PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs, Oncogene, 30, 3222, 10.1038/onc.2011.42
Wiestner, 2012, Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia, 88
Yalon, 2011, Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex, Childs Nerv Syst, 27, 179, 10.1007/s00381-010-1222-y
Yao, 2011, Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, 364, 514, 10.1056/NEJMoa1009290
Yap, 2011, First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors, J Clin Oncol, 29, 4688, 10.1200/JCO.2011.35.5263
Zeng, 2012, Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment, Blood, 120, 2679, 10.1182/blood-2011-11-393934
Zhao, 2008, Class I PI3K in oncogenic cellular transformation, Oncogene, 27, 5486, 10.1038/onc.2008.244